Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical wnt pathway

Diabetes

Volumn 62, Issue 12, 2013, Pages 4228-4238

  Liu, Xiaochen ^a,b   Zhang, Bin ^c   McBride, Jeffrey D ^b   Zhou, Kevin ^b   Lee, Kyungwon ^b   Zhou, Yueping ^a   Liu, Zuguo ^a   Ma, Jian Xing ^b  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; INTRACELLULAR ADHESION MOLECULE; KALLISTATIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; SERINE PROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEUKOSTASIS; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBSERVATIONAL STUDY; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECRETION; RECEPTOR BINDING ASSAY; RETINA CELL; RETINA NEOVASCULARIZATION; TRANSGENIC MOUSE; WNT SIGNALING PATHWAY;

ANIMALS; CYTOKINES; DIABETIC RETINOPATHY; INTERCELLULAR ADHESION MOLECULE-1; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MICE; MICE, TRANSGENIC; PERMEABILITY; RETINA; RETINAL NEOVASCULARIZATION; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT SIGNALING PATHWAY;

EID: 84891767239     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1710     Document Type: Article

References (49)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974
2. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248
3. Huang H, Campbell SC, Nelius T, et al. Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 2004;112:1042-1048
4. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245-3252
5. Chao J, Chai KX, Chen LM, et al. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990;265:16394-16401
6. Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999;47:221-228
7. Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006;17:1201-1213
8. Ma JX, King LP, Yang Z, Crouch RK, Chao L, Chao J. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res 1996;15:1117-1123
9. Jenkins AJ, McBride JD, Januszewski AS, et al. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res 2010;2:19
10. Reis M, Liebner S. Wnt signaling in the vasculature. Exp Cell Res 2013;319: 1317-1323
11. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810
12. Gong Y, Slee RB, Fukai N, et al.; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-523
13. Toomes C, Bottomley HM, Jackson RM, et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet 2004;74:721-730
14. Chen Y, Hu Y, Zhou T, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 2009;175:2676-2685
15. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001;44:757-765
16. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-111
17. Zhang SX, Ma JX, Sima J, et al. Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol 2005;166:313-321
18. Chen CH, Dixon RA, Ke LY, Willerson JT. Vascular progenitor cells in diabetes mellitus: roles of Wnt signaling and negatively charged low-density lipoprotein. Circ Res 2009;104:1038-1040
19. Zhang B, Abreu JG, Zhou K, et al. Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci USA 2010;107:6900-6905
20. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. J Biol Chem 2009; 284:3323-3333
21. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996;80:241-245
22. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909
23. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-584
24. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol 2009;219:446-454
25. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-1137
26. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014
27. Chao J, Stallone JN, Liang YM, Chen LM, Wang DZ, Chao L. Kallistatin is a potent new vasodilator. J Clin Invest 1997;100:11-17
28. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001;489:270-276
29. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003;9:244-250
30. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-2645
31. Huang Q, Wang S, Sorenson CM, Sheibani N. PEDF-deficient mice exhibit an enhanced rate of retinal vascular expansion and are more sensitive to hyperoxia-mediated vessel obliteration. Exp Eye Res 2008; 87:226-241
32. Smith LE. Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl 2002;91:26-28
33. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygeninduced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 2009;4:1565-1573
34. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 2005;166:637-644
35. Banin E, Dorrell MI, Aguilar E, et al. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci 2006;47:2125-2134
36. Bai YJ, Huang LZ, Zhou AY, Zhao M, Yu WZ, Li XX. Antiangiogenesis effects of endostatin in retinal neovascularization. J Ocul Pharmacol Ther 2013;29:619-626
37. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis 2007;13:840-853
38. Shen B, Gao L, Hsu YT, et al. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 2010;299:H1419-H1427
39. Shah CA. Diabetic retinopathy: A comprehensive review. Indian J Med Sci 2008;62:500-519
40. Xu H, Forrester JV, Liversidge J, Crane IJ. Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest Ophthalmol Vis Sci 2003;44:226-234
41. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005;46: 2210-2218
42. Serra AM, Waddell J, Manivannan A, Xu H, Cotter M, Forrester JV. CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation. Am J Pathol 2012;181:719-727
43. Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 1993;120:545-556
44. Diamond MS, Staunton DE, de Fougerolles AR, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990;111:3129-3139
45. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398
46. Maretto S, Cordenonsi M, Dupont S, et al. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 2003;100:3299-3304
47. Lee K, Hu Y, Ding L, et al. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes 2012;61:2948-2957
48. Park K, Lee K, Zhang B, et al. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol 2011;31:3038-3051
49. Cha B, Kim W, Kim YK, et al. Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling. Oncogene 2011;30:2379-2389